|
Accession number;05A0136074
|
| Title;Chronic myelogenous leukemia. |
| Author;
SHIGENO KAZUYUKI
(Hamamatsu Univ. Sch. of Med.)
ONISHI KAZUNORI
(Hamamatsu Univ. Sch. of Med.)
|
Journal Title;Modern Medical Laboratory
|
Journal Code:Z0084B
|
ISSN:0301-2611
|
|
VOL.33;NO.1;PAGE.6-11(2005)
|
| Figure&Table&Reference;FIG.5, TBL.2, REF.5 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Chronic myelogenous leukemia (CML) is a disease which is caused by bcr-abl gene generated by the mutual translocation of abl gene on the 9th chromosome and bcr gene on the 22nd chromosome. An inhibitor for tyrosine kinase of BCR-ABL protein, imatinib methylate, has been developed, and attracting attentions as a molecular target therapy. It is a drug synthesized chemically to affect only on the molecule as the purpose, and it is advantageous in that it is highly effective for leukemia, and at the same time, it alleviates the noxious phenomena for other cells and tissues. Owing to the appearance of imatinib methylate, the therapeutic strategy for CML seemed to have changed greatly from the conventional therapy with interferon (IFN) as a core. The result in the long-term prognosis is expected in future. |
|
|
|
Related Articles;
|
